Front. Cell Dev. Biol. Frontiers in Cell and Developmental Biology Front. Cell Dev. Biol. 2296-634X Frontiers Media S.A. 10.3389/fcell.2021.753706 Cell and Developmental Biology Review Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications Wang Maoye 1 † Gu Jianmei 2 † Zhang Xu 1 Yang Jianping 3 * Zhang Xiaoxin 1 * Fang Xinjian 4 * 1Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China 2Department of Clinical Laboratory Medicine, Nantong Tumor Hospital, Nantong, China 3Department of Orthopedics, Changzhou Traditional Chinese Medicine Hospital, Changzhou, China 4Department of Oncology, Lianyungang Hospital Affiliated to Jiangsu University, Lianyungang, China

Edited by: Feng Wang, Affiliated Hospital of Nantong University, China

Reviewed by: Weifeng Ding, Nantong University, China; Bangshun He, Nanjing Medical University, China

 *Correspondence: Jianping Yang, 43655304@qq.com Xiaoxin Zhang, zhangxiaoxin2014@163.com Xinjian Fang, lygfxj@126.com

†These authors have contributed equally to this work

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Cell and Developmental Biology

 15 10 2021 2021 9 753706 05 08 2021 20 09 2021 Copyright © 2021 Wang, Gu, Zhang, Yang, Zhang and Fang. 2021 Wang, Gu, Zhang, Yang, Zhang and Fang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Long non-coding RNA (lncRNA) DANCR (also known as ANCR)—differentiation antagonizing non-protein coding RNA, was first reported in 2012 to suppress differentiation of epithelial cells. Emerging evidence demonstrates that DANCR is a cancer-associated lncRNA abnormally expressed in many cancers (e.g., lung cancer, gastric cancer, breast cancer, hepatocellular carcinoma). Increasing studies suggest that the dysregulation of DANCR plays critical roles in cancer cell proliferation, apoptosis, migration, invasion, and chemoresistance in vitro and tumor growth and metastasis in vivo. Mechanistic analyses show that DANCR can serve as miRNA sponges, stabilize mRNAs, and interact with proteins. Recent research reveals that DANCR can be detected in many body fluids such as serum, plasma, and exosomes, providing a quick and convenient method for cancer monitor. Thus DANCR can be used as a promising diagnostic and prognostic biomarker and therapeutic target for various types of cancer. This review focuses on the role and mechanism of DANCR in cancer progression with an emphasis on the clinical significance of DANCR in human cancers.

 long non-coding RNA DANCR cancer biomarker diagnosis therapy target Introduction

LncRNAs are non-coding RNAs (ncRNAs) consisting of longer than 200 nucleotides in length without initiation codon and termination codon. They were initially considered as “junk” transcriptional products without biological functions, thus attracting limited attention among scientists (Anastasiadou et al., 2018). However, in recent decades, large-scale genome-wide sequencing analysis has shown the tissue specificity and essential functions of non-coding RNAs in diverse biological processes (Fico et al., 2019). They can modulate gene expression at epigenetic, transcription, and post-transcription levels (Ma et al., 2019).

LncRNAs also play essential roles in human cancers. The previous studies have indicated that many lncRNAs are dysregulated in cancers (Iyer et al., 2015; Yan et al., 2015). Aberrant expression of lncRNAs is associated with tumor growth (Zhou et al., 2020), metastasis (Liao et al., 2021), angiogenesis (Jin et al., 2020), chemotherapy resistance (Ferretti and León, 2021), and metabolism (Xu et al., 2021). Therefore, lncRNAs are regarded as important regulators of the pathological processes in cancer cells.

Differentiation antagonizing non-protein coding RNA (DANCR or ANCR), located on human chromosome 4q12, was first reported in 2012 to suppress differentiation of epithelial cells, and then proved to promote the stemness features of hepatocellular carcinoma cells (Kretz et al., 2012; Yuan et al., 2016). Subsequently, in recent decades, many studies have been carried out to understand the function of DANCR in cancer. DANCR is aberrantly expressed in various kinds of cancers (Figure 1). The dysregulation of DANCR expression is closely associated with biological functions (Figure 2) and clinical pathological factors (Figure 3). In this review, we summarized the current evidence regarding the function and underlying mechanism of DANCR in numerous cancers. It is suggested that DANCR serve as a tumor promoter or suppressor, representing a promising cancer biomarker or therapeutic target in various cancers.

The dysregulation of DANCR expression in human cancers.

The biological function of DANCR in different cancers.

The correlation of DANCR expression level with clinicopathological factors of patients with cancers.

 Regulatory Mechanisms for DANCR

The downstream regulatory mechanisms for the biological roles of DANCR in cancers are complicated (Figure 4). The competing endogenous RNA (ceRNA) network, initially proposed in 2011, is one popular regulatory mechanism of DANCR in cancers (Table 1; Salmena et al., 2011). As we know, miRNAs could regulate gene expression at the post-transcriptional level by interacting with the 3′UTR region of mRNA via base-pairing (Fabian et al., 2010). Meanwhile, the miRNA recognition elements (MRE) of ceRNA could compete with relevant miRNAs to bind to mRNAs and regulate their expression (Salmena et al., 2011). Up to now, DANCR has been reported to bind to ∼ 50 miRNAs (Table 1).

The upstream and downstream regulatory mechanisms for DANCR in cancer. For upstream mechanisms, factors like proteins or drugs can regulate the expression of DANCR. Meanwhile, methylation modification can also regulate DANCR expression. For downstream mechanisms, DANCR can act to sponge miRNAs, stabilize mRNAs and interact with proteins, finally regulating the activation of many signaling pathways.

The molecular mechanisms of DANCR in various cancers.

Cancer Role Regulated molecules
 Related pathway References
miRNA mRNA Protein
Tongue squamous cell carcinoma Oncogene miR-135a-5p KLF8 DANCR/miR-135a-5p/KLF8 Zheng et al., 2019
Esophageal squamous cell carcinoma Oncogene miR-33a-5p; miR-4707-3p FOXC2 ZEB1 DANCR/miR-33a-5p/ZEB1; ZNF750 mutation/DANCR/miR-4707-3p/FOXC2 Zhang C. et al., 2019; Bi et al., 2020
Gastric cancer Oncogene MDR1 and MRP1 SALL4; FoxO1 SALL4/DANCR/β-catenin pathway; DANCR/FoxO1; P-gp and MRP1 pathways Pan et al., 2018; Xie et al., 2020; Xu et al., 2019
Colorectal cancer Oncogene miR-577; miR-185-5p; miR-518a-3p; miR-125b-5p; miR-145-5p HSP27; HMGA2; MDMA; HK2; NRAS; MALAT1 KAT6A; EZH2; QK DANCR/miR-577/HSP27; DANCR/miR-185-5p/HMGA2; DANCR/miR-518a-3p/MDMA; DANCR/miR-125b-5p/HK2; DANCR/miR-145-5p/NRAS; DANCR/KAT6A acetyltransferase activity; DANCR-EZH2; Doxorubicin/DANCR/QK/MALAT1 Yang et al., 2017; Wang et al., 2018b; Lian et al., 2020; Shi et al., 2020; Sun et al., 2020; Bahreini et al., 2021; Lu et al., 2021; Xiong et al., 2021
Hepatocellular carcinoma Oncogene miR-216a-5p; miR-27a-3p; miR-125b-5p; miR-140-3p; miR-222-3p; miR-214, miR-1254, miR-199a, and miR-605; miR−214, and miR−320a KLF12; LIMK1; HNRNPA1; ATG7; PSMD10; CTNNB1 p-p38/p38, p-ERK1/2/ERK1/2, p-JNK/JNK DANCR/miR-216a-5p/KLF12; DANCR/miR-27a-3p/LIMK1; ROCK1/LIMK1/COFILIN1; DANCR/miR-125b-5p; MAPK signaling pathway; DANCR/miR-140-3p/HNRNPA1 DANCR/HNRNPA1; DANCR/miR-222-3p/ATG7; DANCR/miR-214, miR-1254, miR-199a or miR-605; DANCR/PSMD10/IL-6/STAT3/DANCR; DANCR/miR-214, miR-320a/CTNNB1 Yuan et al., 2016; Guo D. et al., 2019; Wang J. et al., 2019; Liu et al., 2020a; Wang X. et al., 2020; Wen et al., 2020; Yang et al., 2020
Tumor suppressor Wnt/β-catenin signaling pathway Song et al., 2020
Cholangiocarcinoma Oncogene miR-345-5p TWIST1; FBP1 EZH2 DANCR/miR-345-5p/Twist1; DANCR-EZH2/FBP1 Wang N. et al., 2019; Zhu et al., 2020
Pancreatic cancer Oncogene miR-135a; miR-214-5p; miR-33b NLRP37; E2F2; MMP16 MLL3; IGF2BP2 DANCR/miR-135a/NLRP37; DANCR/miR-214-5p/E2F2; DANCR/miR-33b/MMP16; DANCR/MLL3 (advanced stages); IGF2BP2/DANCR (m6A modified) Luo et al., 2019; Yao et al., 2019; Hu et al., 2020; Liu et al., 2020b; Tang et al., 2020
Nasopharyngeal carcinoma Oncogene miR-4731 HIF1A; PTEN; SOX2; NMT1 NF90/NF45; EZH2; RBM3; STAT3 DANCR- (NF90/NF45)/HIF-1α; DANCR-EZH2/PTEN; Resveratrol/DANCR-EZH2/PTEN; DANCR-RBM3/SOX2; IL-6/JAK1/STAT3; DANCR/miR-4731-5p/NMT1 Ma X. et al., 2018; Wen et al., 2018; Zhang X. et al., 2019; Li et al., 2020; Zhang J. et al., 2020; Ma et al., 2021
Lung cancer Oncogene miR-216a; miR-496; miR-1225-3p; miR-758-3p; miR-138; miR-214-5p MTOR; ERBB2; SOX4; CIZ1; KRAS; HMGA2 EZH2; HMGA2 DANCR/miR-216a; Wnt/β-catenin signaling pathway; DANCR/miR-496/mTOR; DANCR/miR-1225-3p/ErbB2; DANCR/miR-758-3p; DANCR/miR-138/Sox4; DANCR/miR-214-5p/CIZ1; DANCR-EZH2/p21 Lu Q.C. et al., 2018; Wang and Jiang, 2018; Zhen et al., 2018; Bai et al., 2019; Guo L. et al., 2019; Zhang and Jiang, 2019; Chen Y.R. et al., 2020; Yu et al., 2020; Huang et al., 2021
Tumor suppressor TGFB1 TGF-β1 TGF-β signaling Wang et al., 2018a
Osteosarcoma Oncogene miR-149; miR-33a-5p; miR-216a-5p; miR-335-5p; miR-1972 MSI2; AXL; SOX5; ROCK1; KRAS and CDKN1B EZH2; p-p38MAPK DANCR/miR-149/MSI2; DANCR/miR-33a-5p/AXL; AXL-Akt pathway; DANCR/miR-216a-5p/SOX5; DANCR/miR-335-5p or miR-1972/ROCK1; DANCR-EZH2/p21 and p27; p38MAPK signaling pathway Jiang et al., 2017; Zhang and Peng, 2017; Wang et al., 2018c; Liu et al., 2019; Pan et al., 2020; Zhang W. et al., 2020
Breast cancer Oncogene miR-758-3p; miR-874-3p; miR-4319; miR-216a-5p; PAX6; SOX2; SOCS3; CD44, ABCG2; TUFT1; EZH2; RXRA DANCR/miR-758-3p/PAX6; TUFT1/DANCR/miR-874-3p/SOX2; DANCR/miR-4319/VAPB; DANCR/miR-216a-5p; DANCR-EZH2/SOCS3; DANCR-EZH2/CD44, ABCG2; PI3K/AKT signaling Sha et al., 2017; Tang et al., 2018; Tao et al., 2019; Jia et al., 2020; Wu et al., 2020; Zhang K.J. et al., 2020; Zhang X.H. et al., 2020
Tumor suppressor RUNX2 EZH2 DANCR-EZH2; TGF-β/DANCR/RUNX2 Li et al., 2017b,c
Prostate cancer Oncogene miR-135a; miR-34a-5p; miR-214-5p; miR-185-5p JAG1; LASP1; TIMP2/3 EZH2; MYC, and p21 DANCR/miR-135a; DANCR/miR-34a-5p/JAG1; DANCR/miR-214-5p/TGF-β; DANCR/miR-185-5p/LASP1; AK/PI3K/AKT/GSK3β/snail; DANCR-EZH2/TIMP2/3 Jia et al., 2016; Lu Y. et al., 2018; Ma et al., 2019; Zhao et al., 2019; Deng et al., 2021; Sun et al., 2021
Ovarian cancer Oncogene miR-145; miR-214 KLF5 SP1; UPF1 DANCR/miR-145/VEGF; TGF-β/DANCR/miR-214/KLF5; SP1/DANCR; DANCR/UPF1 Lin et al., 2019; Pei et al., 2019; Cui et al., 2020; Huang et al., 2020
Cervical cancer Oncogene miR-335-5p; miR-665; miR-145-3p TGFBR1; FRAT1 and FRAT2 KLF5, ZEB1; FRAT1 and FRAT2 DANCR/miR-335-5p/ROCK1; DANCR/miR-665/TGFBR1; ERK/SMAD pathway; KLF5/DANCR/miR-145-3p/ZEB1; Wnt/β-catenin signaling pathway Cao et al., 2019; Liang et al., 2019; Tian et al., 2020; Hu et al., 2021
Tumor suppressor HIF-1α DANCR/HIF-1α Ta et al., 2020
Bladder cancer Oncogene miR-149; miR-335 MSI2; VEGF-C CCND1 DANCR/miR-149/MSI2; IL-11-STAT3 signaling; DANCR/miR-335/VEGF-C Zhan et al., 2018; Chen et al., 2019; Ping et al., 2021
Glioma Oncogene miR-33a-5p; miR-634; miR-216a; miR-33a-5p, miR-33b-5p, miR-1-3p, miR-206, and miR-613 RAB1A; LGR5; AXL; KLF8 EZH2, PTEN DANCR/miR-33a-5p; DANCR/miR-634/RAB1A; DANCR/miR-216a/LGR5, PI3K/AKT signaling pathway; AXL/PI3K/Akt/NF-κB; Wnt/β-catenin signaling pathway; DANCR-EZH2/PTEN Li and Zhou, 2018; Ma Y. et al., 2018; Xu et al., 2018; Yang et al., 2018; Wang W. et al., 2019; Cheng et al., 2020

In addition to binding to miRNAs, DANCR could also interact with mRNAs or proteins. For example, DANCR was verified to interact with 3′UTR of CTNNB1 mRNA in hepatocellular carcinoma, thus competitively blocking miRNA site and reversing miRNA-mediated CTNNB1 suppression (Yuan et al., 2016). Similarly, in sorafenib-resistant HCC, DANCR could bind with PSMD10 mRNA to stabilize its expression via blocking the miRNA binding site (Liu et al., 2020a). In the case of binding to proteins, it is interesting that DANCR could regulate both protein stability (Wen et al., 2020) and protein degradation (Xie et al., 2020).

Another function of DANCR is epigenetic regulation. EZH2, a histone methyltransferase of polycomb repressive complex 2 (PRC2), is a common binding protein for DANCR. By interacting with EZH2, DANCR could epigenetically silence target gene transcription. In cholangiocarcinoma, DANCR-EZH2 interaction promoted FBP1 silence by regulating histone methylation of FBP1 promoter and then exacerbating tumorigenesis (Wang N. et al., 2019).

What’s more, DANCR expression is regulated at both epigenetic and transcriptional levels. It was suggested that in gastric cancer cells, DANCR could be activated by SALL4, which could bind to the promoter of DANCR (Pan et al., 2018). In addition, DANCR has been considered as a drug target. In nasopharyngeal carcinoma, resveratrol was verified to suppress cancer progression via DANCR/PTEN pathway (Zhang J. et al., 2020). Moreover, IGF2BP2 protein has been shown to regulate DANCR stability by m6A modification (Hu et al., 2020). In conclusion, the upstream and downstream mechanisms of DANCR are multifaceted and play vital roles in human cancers.

 Diagnostic Value of DANCR

It has been verified that DANCR is aberrantly expressed in many cancers. Notably, DANCR is detected in some body fluids, including serum, plasma, and even exosomes (Table 2). This indicates that DANCR may help diagnosis and prognosis in many cancers by non-invasive methods with low cost and real-time monitoring.

The diagnostic and prognostic value of DANCR in cancer.

Cancer Marker Sensitivity Specificity AUC Distinction Source Detection method References
Gastric cancer DANCR 64.6% 67.7% 0.704 GC (n = 65)/paired adjacent normal tissues (ANT) (n = 65) Tissues qRT-PCR Pan et al., 2018
72.7% 79.5% 0.816 GC (n = 55)/HV (healthy volunteers) (n = 39) Serum
Colorectal cancer DANCR 67.5% 82.5% 0.747 CRC (n = 40)/HV (n = 40) Serum qRT-PCR Shen et al., 2020
CEA 40.0% 85% 0.623
CA199 32.5% 80% 0.573
DANCR + CEA + CA199 87.5% 55% 0.812
DANCR 67.5% 87.5% 0.745 CRC (n = 40)/colorectal polyps (n = 10)
CEA – – 0.555
CA199 – – 0.542
DANCR 87.5% 72.5% 0.732 CRC tissues (n = 40)/ANT (n = 40) Tissues qRT-PCR Bahreini et al., 2021
Hepatocellular carcinoma DANCR(>−6.2 dCt)DANCR(T/ANT >1.1) 91.2% 88.9% 42.9% 49.1% 0.69 0.74 HCV-HCC recurrence (n = 126)/without recurrence (n = 57) after curative surgical resection Tissues qRT-PCR Wang S.C. et al., 2020
83.5% 94.6% 0.88 HCV-HCC recurrence (n = 121)/without recurrence (n = 56) after curative surgical resection Exosomes ddPCR
68.3% 85.7% 0.831 qRT-PCR
DANCR 83.8% 72.7% 0.868 HCC (n = 52)/HV, CHB and cirrhosis (n = 94) Plasma qRT-PCR Ma et al., 2016
AFP 65.4% 77.7% 0.744
DANCR 80.8% 84.3% 0.864 HCC (n = 52)/CHB and cirrhosis (n = 51)
AFP 55.8% 76.5% 0.650
Lung cancer DANCR – – 0.9265 NSCLC (n = 72)/HV (n = 44) Tissues qRT-PCR Wang et al., 2018a
– – 0.8831 Plasma
Prostate cancer DANCR – – 0.852 PC patients (n = 53)/HV (n = 47) Serum qRT-PCR Deng et al., 2021)
Ovarian cancer DANCR – – 0.852 OC tissues (n = 20)/ANT (n = 20) Tissues qRT-PCR Pei et al., 2019
Cervical cancer DANCR – – 0.9073 HPV-negative CSCC (n = 38)/HV (n = 38) Tissues qRT-PCR Ta et al., 2020
– – 0.8740 Serum
Papillary thyroid cancer DANCR 85.29% 66.18% 0.8233 PTC tissues (n = 76)/ANT (n = 76) Tissues qRT-PCR Zhang K. et al., 2019
81.54% 82.22% 0.8756 PTC (n = 49)/HV (n = 45) Tissues (GSE33630)
83.33% 91.67% 0.9167 PTC (n = 57)/HV (n = 9) Tissues (GSE50901)
72.41% 70.83% 0.704 PTC I/II patients (n = 57)/III/IV patients (n = 19) Tissues
Brain tumors DANCR 91.67% 0.9231% 0.91 Glioma (n = 13)/meningioma (n = 13) Tissues qRT-PCR Malakootian et al., 2018
91.67% 0.7778% 0.84 Meningioma (n = 13)/pituitary adenoma (n = 9)

Circulating DANCR expression is also positively associated with tissue DANCR level. For example, after HCC surgery treatment, plasma DANCR level decreased dramatically, which indicates that circulating DANCR may drive from tissues (Ma et al., 2016). As expected, the release of RNAs to circulation may reveal disease-associated information of tissue or activation of intercellular signaling pathways (Misawa et al., 2017). Thus, circulating DANCR may have a diagnostic capability. It was reported by Ma et al. (2016) that plasma DANCR had a better diagnostic value than AFP in HCC. As illustrated in Table 2, plasma DANCR (AUC = 0.868) showed a better effect in distinguishing HCC from healthy volunteers (HV), patients with CHB (chronic hepatitis B), and cirrhosis than AFP (AUC = 0.744). Recently, it has been confirmed that DANCR can be transported through exosomes, but the detailed mechanism is unclear. In addition, droplet digital PCR (ddPCR) has been used to detect exosomal DANCR to monitor HCV-HCC recurrence after curative surgical resection, showing a higher AUC (0.88) than qRT-PCR detection (0.831) (Wang S.C. et al., 2020).

These encouraging researches indicate that circulating DANCR may be a novel non−invasive biomarker for cancer diagnosis. However, the lncRNA-based liquid biopsy is still at its early stage. For further application, there is still a long way to go. For instance, standardized sample preparation and reliable endogenous controls need to be considered.

 Function and Mechanism of DANCR in Human Cancers Digestive System Tongue Squamous Cell Carcinoma

Tongue squamous cell carcinoma (TSCC) is one of the most common oral cavity malignancies, known for its aggressive biological behavior (Boldrup et al., 2017). Although significant progress has been made in treating TSCC, long-term survival does not improve significantly (Hu et al., 2017). Therefore, it would be beneficial to find promising biomarkers for TSCC detection and treatment.

DANCR expression was upregulated in TSCC cells. In vitro studies showed that DANCR could enhance TSCC cell proliferation, migration, and invasion. The molecular mechanism study suggested that DANCR act as a ceRNA to sponge miR-135a-5p and upregulate Kruppel-like Factor 8 (KLF8) expression. Similarly, knockdown of DANCR inhibited tumor growth and KLF8 expression in vivo, suggesting that DANCR may play an essential role via miR-135a-5p/KLF8 axis (Zheng et al., 2019). So DANCR may be a diagnostic biomarker and new therapeutic target in TSCC.

 Esophageal Cancer

Esophageal cancer (EC) is one of the most frequent cancers in the digestive system and ranks the seventh leading cause of death in cancers (Siegel et al., 2021). Though the management and treatment of EC patients have improved, there is still no effective treatment, and 5-year post-esophagectomy survival rates are still poor (Hou et al., 2017; Huang and Yu, 2018). In addition, due to the deficiency of early clinical symptoms, it tends to be diagnosed in advanced stages (Encinas de la Iglesia et al., 2016).

Esophageal squamous cell carcinoma (ESCC) is one histological subtype of EC (Le Bras et al., 2016). Shi et al. (2018) monitored the expression of DANCR in ESCC, and they found that ESCC cell lines and tissues expressed a higher level of DANCR compared with that in adjacent normal counterparts. Its aberrant expression was implicated in accelerating cell proliferation, migration, invasion, and inhibiting apoptosis. Subsequently, Zhang C. et al. (2019) investigated the role of DANCR in ESCC. They found that DANCR sponged miR-33a-5p and upregulated zinc-finger-enhancer binding protein 1 (ZEB1) expression. Recently, Bi et al. (2020) discovered that DANCR was a direct downstream target of a tumor suppressor gene ZNF750. The mutations or deletions of ZNF750 were significantly associated with upregulated DANCR and poor prognosis, especially tumor metastasis in ESCC patients. Their further investigations verified that DANCR could competitively bind with miR-4707-3p and serve as a ceRNA to regulate FOXC2 expression in ESCC, which provides a novel DANCR/miR-4707-3p/FOXC2 pathway regulated by ZNF750 in ESCC. In summary, DANCR is associated with ESCC progression, and it may act as a novel prognostic and therapeutic target for ESCC.

 Gastric Cancer

Gastric cancer (GC) is a complex and heterogeneous disease, regarded as the fourth leading cause of cancer-related death (Serra et al., 2019). Traditional clinical indicators such as CEA, CA199, and CA724 are faced with shortcomings in diagnostic sensitivity and specificity. Therefore, there is an urgent need to find a potential marker for GC with higher diagnostic sensitivity and specificity (Cai et al., 2019).

Recent studies have revealed that DANCR expression was upregulated in GC tissues (Hao et al., 2017) and cell lines (Pan et al., 2018) compared to adjacent normal ones. High DANCR expression promoted cell proliferation, migration, and invasion in GC cells. Its expression was positively associated with tumor size, lymph node metastasis, invasion depth, and TNM stage of GC patients (Pan et al., 2018), suggesting that DANCR may correlate to the malignant progression of GC. For further function and mechanism analysis of DANCR in GC, Pan et al. (2018) proved that DANCR was regulated by SALL4 (sal-like protein 4), previously shown as a critical transcription factor to regulate the stemness of GC cells. Then DANCR accelerated GC progression via Wnt/β-catenin pathway (Zhang et al., 2014; Pan et al., 2018). A study by Xie et al. (2020) indicated another mechanism showing that DANCR inhibited FOXO1 expression by promoting its ubiquitination. As a result, M1 macrophage polarization was inhibited, which promoted GC cell invasion and metastasis.

Chemotherapy is the primary therapy for GC patients with unresectable tumors, and cisplatin (DDP) is used as the first-line drug (Zhu et al., 2019). However, DDP resistance is a major obstacle for DDP application. Thus, exploring underlying mechanisms of DDP-resistance development in GC remains an urgent issue (Guo Q. et al., 2019). Xu et al. (2019) found that DANCR was upregulated in DDP-resistant GC cells. Further study showed that the expression of multidrug resistance (MDR) related genes, MDR1 and MRP1, were induced by DANCR in GC cells. Their studies suggest that DANCR is associated with MDR development and may be a potential therapeutic target for GC with MDR.

 Colorectal Cancer

Colorectal cancer (CRC) is one of the most commonly diagnosed malignant neoplasms among men (Siegel et al., 2019, 2021). Thanks to the improvements in screening tests and treatment, CRC incidence and mortality rates have declined for several years in developed countries (Siegel et al., 2017). However, in some low-income and middle-income regions, CRC incidence and mortality rates are still rising rapidly. Consequently, improvement in treatment options and accessibility is still necessary for economically backward areas (Arnold et al., 2017).

Liu et al. (2015) demonstrated that CRC tissues expressed a higher level of DANCR than adjacent normal ones. In addition, high DANCR expression was associated with worse overall survival and disease-free survival, and further study showed that DANCR might be an independent prognostic factor for CRC.

A recent study by Wang et al. (2018b) showed that miR-577 shared the same binding site for HSP27 (heat shock protein 27) with DANCR. They verified DANCR could enhance CRC cell proliferation and metastasis by acting as a miRNA sponge to promote HSP27 expression. Moreover, in in vivo study, the elevation of DANCR promoted tumor growth and liver metastasis of CRC. Another mechanism study by Lian et al. (2020) identified that DANCR could bind with lysine acetyltransferase 6A (KAT6A) and then triggered H3K23 acetyltransferase activity to promote CRC development. Intriguingly, DANCR could also promote the expression of an oncogenic lncRNA MALAT1 via enhancing its RNA stability, which suppressed doxorubicin-induced apoptosis in CRC cells (Xiong et al., 2021). In summary, these studies provided a potential therapeutic target for molecular treatment in CRC.

DANCR was also overexpressed in the serum of CRC patients. Serum DANCR level was positively associated with the TNM stage. Surprisingly, serum DANCR showed a better diagnostic ability than CEA and CA199 and a better performance in distinguishing CRC and colorectal polyps. Moreover, the combination of DANCR with CEA and CA199 showed better sensitivity than the single or double combination (Shen et al., 2020; Table 1), suggesting that DANCR has the potential to be a promising biomarker for CRC patients.

 Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and ranks the sixth most common neoplasm and the third leading cause of cancer-related death (Forner et al., 2018). Sorafenib is an anti-angiogenic multi-kinase inhibitor for advanced hepatocellular carcinoma. However, the outcomes after therapy are not encouraging (Llovet et al., 2008). So, it is urgent to find other available opinions for treatment. As shown in recent studies, non-coding RNAs are considered promising biomarkers for diagnosis and treatment (Duan et al., 2019).

DANCR was upregulated in HCC cell lines, tissues, plasma and exosomes (Ma et al., 2016; Wang S.C. et al., 2020; Wen et al., 2020). It was implicated that DANCR played an essential role in HCC progression. For example, a high level of DANCR was associated with stemness features (Yuan et al., 2016), metastasis (Wen et al., 2020), and chemotherapeutic drug resistance in HCC (Liu et al., 2020a). In addition, the ROC (receiver operating characteristic) analysis showed that plasma DANCR and exosomal DANCR exhibited good discriminatory ability, suggesting it could be a promising diagnostic marker (Ma et al., 2016; Wang S.C. et al., 2020; Table 2).

DANCR could act as sponges for multiple miRNAs including miR-216a-5p (Wang J. et al., 2019), miR-27a-3p (Guo D. et al., 2019), miR-125b-5p (Yang et al., 2020), miR-140-3p (Wen et al., 2020) and miR-222-3p (Wang X. et al., 2020) in HCC. DANCR could also stabilize PSMD10 (Liu et al., 2020a) and CTNNB1 (Yuan et al., 2016) mRNAs by binding to their 3′UTR region to prevent its degradation by miRNAs. Wen et al. (2020) found that DANCR could not only improve HNRNPA1 expression via DANCR/miR-140-3p/HNRNPA1 axis but also bind to HNRNPA1 protein and inhibit its degradation. However, DANCR was also considered as a tumor suppressor due to the suppression of Wnt/β-catenin signaling pathway in HCC (Song et al., 2020).

In conclusion, DANCR is a crucial factor in HCC progression and may serve as a new marker for HCC diagnosis and treatment.

 Cholangiocarcinoma

Cholangiocarcinoma (CCA) is a rare but aggressive biliary epithelial tumor (Goyal et al., 2021). Surgery is the best therapeutic option; however, only a minority (35%) of CCA patients are diagnosed early, whereas most of them are diagnosed late due to the “silent” clinical character (Rizvi et al., 2018). Therefore, there is an urgent need for early diagnosis and new treatment methods to help improve CCA survival outcomes.

DANCR was overexpressed in CCA tissues compared with adjacent normal tissues. Its expression level was associated with tumor size, TNM stage, and lymph node metastasis. Moreover, CCA patients with higher levels of DANCR had a lower survival rate. Knockdown of DANCR impeded cell proliferation, migration, invasion, EMT process, angiogenesis, and enhanced apoptosis in vitro. miR-345-5p was predicted and verified as a target miRNA of DANCR, which regulated the expression of Twist1 (Twist-related protein 1) in CCA cells (Zhu et al., 2020). Wang N. et al. (2019) showed that DANCR inhibited FBP1 expression epigenetically via interacting with EZH2 and subsequently promoted CCA. In conclusion, DANCR may be a potential biomarker and therapeutic target for CCA.

 Pancreatic Cancer

Pancreatic cancer is the most life-threatening cancer with the lowest 5-year survival rate (10%) (Siegel et al., 2021). What is worse, early detection for pancreatic cancer is lacking, and the available treatment options are limited (Moore and Donahue, 2019).

DANCR showed higher expression in pancreatic cancer cell lines and tissues. Upregulated DANCR expression was associated with poor prognosis and short overall survival time in patients with pancreatic cancer. Knockdown of DANCR suppressed pancreatic cancer cell proliferation, migration, invasion in vitro, and tumor growth in vivo (Luo et al., 2019; Yao et al., 2019). Mechanistic studies showed that DANCR could be methylated at the N6 position of adenosine and then be stabilized by the m6A reader protein IGF2BP2 (Hu et al., 2020). In addition, DANCR sponged several miRNAs to regulate the expression of target mRNAs in pancreatic cancer cells (Luo et al., 2019; Yao et al., 2019; Tang et al., 2020). Interestingly, Liu et al. (2020b) found that DANCR could downregulate MLL3 expression to influence pancreatic cancer progression only at a late stage rather than an early stage.

Hence, DANCR was associated with pancreatic cancer development and regarded as a promising target for pancreatic cancer prognosis and treatment.

 Respiratory System Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is not a common cancer type but notable for its distinctive geographical distribution pattern. Most cases occur in the east and southeast parts of Asia (Chua et al., 2016). NPC patients at an early stage or with locoregional advanced disease could be well treated benefiting from the radiotherapy. However, distant metastasis is the primary cause of treatment failure (Yin et al., 2017).

DANCR was upregulated in NPC and promoted NPC cell proliferation, migration, invasion, and inhibited apoptosis in vitro. In addition, DANCR knockdown inhibited NPC tumor growth in vivo (Hao et al., 2019; Wen et al., 2018). Ma X. et al. (2018) found that DANCR could promote NPC proliferation and radiation resistance via DANCR/PTEN pathway. Interestingly, another research by Zhang J. et al. (2020) found that resveratrol could downregulate the expression of DANCR through this pathway. It validated DANCR as a promising target in NPC therapy.

Hypoxia is known as a target for cancer treatment, including NPC, and intratumoral hypoxia could lead to HIF-1α (hypoxia inducible factor-1α) overexpression (Semenza, 2003; Shan et al., 2018). Wen et al. (2018) found that DANCR overexpression was associated with lymph node metastasis and indicated a poor prognosis in NPC. Further study revealed that DANCR could stabilize HIF-1α mRNA through interacting with NF90/NF45 complex. These data suggest that DANCR might be a potential biomarker and therapeutic target of NPC.

 Lung Cancer

Lung cancer is the leading cause of cancer-related deaths worldwide, both in men and women. It is reported that nearly a quarter of cancer deaths are related to lung cancer (Siegel et al., 2021). Non-small cell lung cancer (NSCLC) accounts for most types of lung cancer, and lung adenocarcinoma is the most common type of NSCLC. Despite improvements in early detection and standard treatment, NSCLC is often diagnosed at an advanced stage with a poor prognosis (Herbst et al., 2008). Understanding the molecular mechanism of NSCLC may bring better treatment for lung cancer.

Upregulated DANCR expression was detected in NSCLC tissue specimens and cell lines compared with normal counterparts. High level of DANCR was associated with larger tumor size, advanced TNM stage, and lymph node metastasis. Bai et al. (2019) found DANCR could activate EMT and act as a ceRNA to competitively bind to miR-138. And then, Sox4, a vital regulator involving tumor growth and metastasis, was regulated. In addition to miR-138, many other miRNAs have been verified as sponge targets for DANCR (Lu Q.C. et al., 2018; Wang and Jiang, 2018; Zhen et al., 2018; Chen Y.R. et al., 2020; Yu et al., 2020; Huang et al., 2021). Another study by Guo L. et al. (2019) showed that DANCR facilitated carcinogenesis by epigenetically silencing p21 expression via binding to EZH2. Thus, DANCR might be a key regulator of lung cancer progression and used as a promising biomarker.

 Genital System Prostate Cancer

Due to PSA testing and advances in early detection and treatment, the death rate for prostate cancer (PCa) dropped by 51% in the past two decades. However, PCa remains the second leading cause of cancer-related deaths in men, and the high rate of overdiagnosis is widely debated. Androgen deprivation therapy (ADT) is the principal treatment for advanced PCa (Magnan et al., 2015; Siegel et al., 2021). However, the majority of PCa will develop into castration-resistant prostate cancer (CRPC) inevitably over time (Nuhn et al., 2019). Compared with ADT, initial treatment with chemotherapy could improve the survival rate (Kahn et al., 2014; Litwin and Tan, 2017). However, the acquisition of chemoresistance inevitably develops, which is a major reason for therapy failure (Domanska et al., 2012).

Strong evidence has been presented about the oncogenic roles of DANCR in PCa. DANCR was upregulated in PCa tissues and cell lines (Jia et al., 2016; Zhao et al., 2019). Lu Y. et al. (2018) found that DANCR expression was induced by MYC, a common oncogene, which resulted in the reduction of p21, a protein required for cell cycle progression. Enzalutamide, a kind of AR (androgen receptor) inhibitor, was used to treat PCa. However, in some cases, it caused side effects such as PCa metastasis (Lin et al., 2013). DANCR knockdown limited the enzalutamide-induced metastasis. Mechanically, DNACR could inhibit TIMP2/3 expression by binding to EZH2 (Jia et al., 2016). Their studies suggested that DANCR might be a potential target for PCa.

Chemotherapy with Taxol (paclitaxel and its semisynthetic analog docetaxel) is commonly used for CRPC. However, there are obstacles to drug resistance (Gan et al., 2009; Jiang and Huang, 2010). Ma et al. (2019) and Zhao et al. (2019) found that DANCR could function as a sponge to miR-135a and miR-34a-5p, and eventually triggered the resistance to paclitaxel and docetaxel, respectively. Meanwhile, DANCR knockdown could promote the sensitivity of PCa cells to these drugs. Thus, DANCR provides a promising target to improve the effectiveness of chemotherapy for PCa.

 Ovarian Cancer

Ovarian cancer (OC) is typically diagnosed at an advanced stage and has no effective screening strategy (Matulonis et al., 2016). Searching available biomarkers and developing appropriate targeted therapies are in need (Cortez et al., 2018).

DANCR was detected upregulated in ovarian cancer tissues and cell lines (Lin et al., 2019). Vascular endothelial growth factor (VEGF) is the master regulator of vessel formation, resulting in the growth and metastasis of tumors (Chen et al., 2018). Lin et al. (2019) suggested that DANCR can facilitate angiogenesis by regulating the DANCR/miR-145/VEGF axis in a manner of ceRNA. Additionally, DANCR showed a cancer-promoting property by negatively regulating UPF1. Enhanced UPF1 in OC cells was able to partly reverse the promotion of cell proliferation and migration by DANCR (Pei et al., 2019). Thus, DANCR might serve as a potential therapeutic target for ovarian cancer treatment.

 Cervical Cancer

Infection of specific types of human papillomavirus (HPV) is the primary biological etiology for cervical cancers (CC). Prophylactic vaccination for HPV provides the most effective method of primary prevention against HPV-related diseases (Kessler, 2017). However, the prognosis of advanced patients with cervical cancer is still poor (Siegel et al., 2021).

Liang et al. (2019) found that the expression of DANCR was aberrantly increased in cervical cancer tissues and cell lines and its high expression was associated with bigger tumor size, advanced FIGO stage, and poorer prognosis. Further functional analysis showed that DANCR could regulate ROCK1 expression by competitively binding to miR-335-5p and promote CC progression. Interestingly, another study by Ta et al. (2020) observed the diagnostic value of DANCR in distinguishing different types of CC. Their further investigation indicated that DANCR downregulated HIF-1α expression and inhibited the growth of HPV-negative CC under hypoxic conditions.

 Breast Cancer

From Cancer statistics 2021, breast cancer (BC) has become the most common type of malignancy among women worldwide, responsible for 15% of deaths in women (Siegel et al., 2021). TNBC (triple-negative breast cancer), with a poor prognosis, is a subtype of breast cancer that does not express ER, PR, and HER2 (Wang X. et al., 2019). Though endocrine and HER2-targeted therapy have made great progress in recent years, targeted therapies for TNBC remain unsatisfactory (Costa et al., 2018). Therefore, it is necessary to identify new molecular targets for breast cancer therapy.

DANCR was significantly upregulated in TNBC tissues and cell lines compared with normal ones (Tang et al., 2018). Sha et al. (2017) found that DANCR expression was increased in TNBC tissues compared with that in adjacent normal tissues. Patients with higher DANCR expression tended to have worse TNM stage and poorer overall survival (OS). Tao et al. (2019) also found that DANCR knockdown significantly suppressed cancer cell proliferation and invasion, while the opposite phenomena were observed when DANCR was overexpressed. Inhibition of DANCR expression also impaired the growth of breast tumors in vivo.

The molecular mechanism analysis showed that DANCR played oncogenic roles by targeting miR-216a-5p as a ceRNA in MDA-MB-231 cells (TNBC cell line) (Tao et al., 2019). In addition, DANCR knockdown was associated with reduced expression of CD44, ABCG2, and ALDH1 in TNBC cells (Sha et al., 2017). Similarly, Tang et al. (2018) showed that DANCR could activate PI3K/AKT signaling through the activation of serine phosphorylation of RXRA by binding of GSK3β and RXRA, which promotes breast cancer progression. Zhang K.J. et al. (2020) verified that DANCR regulated EMT and cancer stemness in BC cells by binding to EZH2, which suppressed SOCS3 (suppressor of cytokine signaling 3) expression. Thus, DANCR was validated as an oncogene in breast cancer, and targeting DANCR may have therapeutic value in BC.

Interestingly, DANCR has also been suggested as a tumor suppressor in BC. Li et al. (2017c) revealed that DANCR expression was downregulated in BC cells as well as tumor tissues. It was verified that DANCR mediated EZH2 degradation and attenuated EMT and metastasis in BC. Another study from the same lab also showed that DANCR could inhibit TGF-β-induced EMT progress and BC metastasis by downregulating RUNX2 expression (Li et al., 2017b; Figure 5).

Mechanism of DANCR in breast cancer.

 Urinary System Bladder Cancer

Bladder cancer (BCa) is among the top ten most common cancer types and the second most common genitourinary malignancy globally, with approximately 550,000 new cases annually (Bhanvadia, 2018; Richters et al., 2019). Diagnosis often occurs too late, particularly in women, due to their misinterpret of hematuria (Grayson, 2017). Thus, it is essential to find potential biomarkers to monitor tumorigenesis, development, and progression in BCa.

Zhan et al. (2018) showed that DANCR was aberrantly upregulated in BCa tissues compared to adjacent normal tissues. Moreover, increased DANCR expression was positively related to higher histological grade and advanced TNM stage. DANCR played as a miRNA sponge to positively regulate the expression of MSI2 (musashi RNA binding protein 2) via sponging miR-149 and subsequently promoted the malignant phenotypes of BCa cells.

Chen et al. (2019) also found that DANCR was significantly upregulated in bladder cancer with lymph node (LN) metastasis. Aberrant expression of DANCR in BCa was associated with LN metastasis and poor prognosis. DANCR guided leucine-rich pentatricopeptide repeat containing (LRPPRC) to stabilize target mRNAs, including IL-11, PLAU, and CCND1. Further investigations indicated that DANCR/LRPPRC/IL-11/STAT3 signaling pathway played an important role in BCa metastasis. These studies suggested that DANCR might be a valuable target for clinical intervention in LN-metastatic BCa.

 Renal Cell Carcinoma

Renal cell carcinoma (RCC) is one of the most common cancers in the urological system, originating from the renal tubular epithelial system. Surgical resection is an available choice for patients with localized RCC. However, due to the lack of sensitivity to radiotherapy and chemotherapy in RCC, targeted therapy is necessary for individuals without conditions for surgery (Lu et al., 2020).

Jin et al. (2017) found that DANCR was down-regulated in RCC tissues compared to adjacent normal tissues. Overexpression of DANCR caused the suppression of RCC cell proliferation, migration and invasion, and the induction of cell apoptosis. miR-3646 and miR-634 were predicted as the downstream targets of DANCR. However, biological validation studies are needed to confirm.

 Endocrine System Papillary Thyroid Cancer

Papillary thyroid cancer (PTC) is the most prevalent form of thyroid cancer with a rapidly increasing incidence without a concomitant rise in mortality (Jegerlehner et al., 2017; Abdullah et al., 2019). Though the mean survival rate after 10 years is higher than 90%, disease recurrence cannot be ignored (Li et al., 2017a). An efficient and accurate diagnosis of PTC is still needed (Zhang H. et al., 2018).

Zhang K. et al. (2019) found that DANCR expression was lower in PTC tissues compared to that in normal thyroid tissues. Its expression was negatively associated with the clinical stage. ROC curve and AUC suggested the clinical diagnosis value of DANCR in PTC, which indicated DANCR might be a potential marker for PTC diagnosis. However, few mechanism studies about DANCR in PTC have been conducted.

 Nervous System Glioma

Glioma is the most frequent and lethal central nervous system (CNS) tumor occurring both in children and adolescents (Sturm et al., 2017). DANCR expression was significantly higher in glioma cells than in normal human astrocytes (Wang W. et al., 2019). DANCR served as a ceRNA to modulate tumorigenesis, growth and metastasis by sponging miR-33a-5p (Yang et al., 2018), miR-634 (Xu et al., 2018), miR-216a (Wang W. et al., 2019) and miR-135a-5p (Feng et al., 2020) via regulating miR-33a-5p axis, miR-634/RAB1A axis, miR-216a/LGR5 axis, and miR-135a-5p/BMI1 axis, respectively. Li and Zhou (2018) also verified that high expression of DANCR might be a poor prognostic factor in glioma patients. Moreover, Ma Y. et al. (2018) found that DANCR promoted cisplatin resistance via activating AXL/PI3K/Akt/NF-κB signaling pathway through competitively binding with miRNAs, including miR-33a-5p, miR-33b-5p, miR-1-3p, miR-206, and miR-613 in glioma. These studies suggested that DANCR would be a potential biomarker for predicting cisplatin sensitivity and a therapeutic target for enhancing cisplatin efficacy in glioma.

 Motor System Osteosarcoma

Osteosarcoma is one of the most common primary solid malignancies of bone and mainly occurs in adolescence. Though the cure rate for conventional treatment of osteosarcoma is close to 70%, once osteosarcoma has spread to distant organs such as lungs, the survival rates are disappointing (Ritter and Bielack, 2010; Fan et al., 2020). Understanding the molecular mechanisms of osteosarcoma might provide new chances for early diagnosis and targets for therapy.

Increased expression of DANCR could be detected in osteosarcoma tissues and cell lines. Enhanced DANCR was found to have a positive correlation with poor prognostic outcomes (Jiang et al., 2017). DANCR suppression could restrain osteosarcoma progression by inhibiting autophagy (Pan et al., 2020). In recent studies, DANCR was found to function as a ceRNA to promote osteosarcoma progression by sponging miR-33a-5p (Jiang et al., 2017), miR-216a-5p (Pan et al., 2020), miR-149 (Zhang W. et al., 2020), miR-335-5p, and miR-1972 (Wang et al., 2018c). The interaction between DANCR and EZH2 was also found in osteosarcoma, which led to the inhibition of p21 and p27 expression. In conclusion, these studies indicated that DANCR could be utilized as a potential therapeutic target for the treatment of osteosarcoma.

 Other Diseases

Not only in cancer, DANCR could also participate in various biological processes and other diseases. Many research indicated that DANCR might play important role in the differentiation of mesenchymal stem cells (MSCs). Zhang J. et al. (2018) found DANCR was downregulated in human bone marrow-derived MSCs (BD-MSCs) during osteogenic differentiation. Their further investigation revealed DANCR could inhibit proliferation and osteogenic differentiation through p38 MAPK pathway. Similarly, Weng et al. (2021) observed the same function of DANCR in osteogenic differentiation and proposed another mechanism hypothesis. They considered that DANCR might suppress osteogenic differentiation via miR-1301-3p/PROX1 axis (Weng et al., 2021). With a similar situation to BD-MSCs, osteogenic differentiation capacity in periodontal ligament stem cells could also be inhibited by DANCR (Wang Z. et al., 2020). Apart from that, DANCR suppressed vascular smooth muscle cells transforming into osteoblast-like cells, thus attenuating arterial calcification (Zhang X. et al., 2020). Moreover, odontoblast differentiation in human dental pulp cells (Chen et al., 2016; Chen L. et al., 2020) and chondrogenic differentiation in human synovium-derived stem cells (Zhang et al., 2017) was inhibited and promoted by DANCR, respectively. To sum up, our increasing knowledge of DANCR indicated that targeting DANCR may be a novel therapeutic method in many diseases.

 Discussion and Conclusion

Dysregulation of lncRNAs is involved in regulating diverse malignant behaviors of cancer cells, leading to cancer progression and metastasis. It indicates that developing new diagnostic methods and therapeutic options targeting lncRNAs may be a new answer to the fight against cancers. LncRNA-DANCR, a booming researching topic in recent years, has been demonstrated to regulate many cellular functions such as proliferation, apoptosis, EMT, and CSC in various human cancers. The mechanism by which DANCR promotes tumor development is extremely complicated, including serving as a ceRNA for miRNAs, interacting with mRNAs or proteins, activating signaling pathways, and regulating epigenetic modulations. This review depicts a comprehensive picture of the biological roles of DANCR and its underlying mechanisms in cancer.

In most cancers, DANCR was upregulated and acted as an oncogene. However, a minority of studies reported that DANCR functioned as a potent tumor suppressor. Even in the same cancer type, the role of DANCR contradicted with each other (Li et al., 2017c; Zhang X.H. et al., 2020). This may be due to the heterogeneity in different cell lines, clinical sample selection, and experimental design (Table 3). Moreover, some of the confusing results in these studies may be explained by dynamic cancer progression. As in pancreatic cancer, MLL3 was only downregulated by DANCR at an advanced stage (Liu et al., 2020b). In addition, the study of gene expression always focuses on bulk analysis, only showing the information of the dominant cellular subset (Kanzaki and Pietras, 2020). Fortunately, emerging single-cell sequencing can reveal the uniqueness of individual cell and provide individualized therapy for patients (Ding et al., 2020). As shown in Figure 4, the downstream mechanisms are complicated. So when focusing on different targets of DANCR, we may come to different conclusions. These conjectures indicate that more studies on DANCR are needed to further clarify its role in specific cancer types and under distinct conditions.

Information of DANCR in breast cancer from six research articles.

Role of DANCR DANCR expression in BC cell lines Compared normal cell line In vitro/in vivo validation Tissue sample size DANCR expression in tissues References
Tumorigenesis ↑: MCF7, T47D, MDA-MB-231, MDA-MB-468 Hs578Bst Both 63 (TNBC)/63 (ANT) ↑: P = 0.009 Sha et al., 2017
Tumorigenesis ↑: MCF7, T47D, BT549, MDA-MB-231, MDA-MB-468, MDA-MB-453 MCF10A Both 60 (TNBC)/10 (normal breast tissue); 60 (TNBC)/15 (Luminal A); 60 (TNBC)/15 (Luminal B) ↑: P < 0.001; ↑: P < 0.05; ↑: P < 0.01 Tang et al., 2018
Tumorigenesis ↑: MCF7, MDA-MB-231 MCF10A Both 57 (TNBC)/57 (ANT) ↑: P < 0.05 Tao et al., 2019
Tumorigenesis ↑: MCF7, T47D, MDA-MB-231, MDA-MB-468 MCF10A Both 46 (BC)/46 (ANT) ↑: P < 0.01 Zhang K.J. et al., 2020
Tumor suppression ↓: MCF7, T47D, BT474, MDA-MB-436, MDA-MB-231, MDA-MB-231HM MCF10A Both 32 (BC)/32 (ANT) ↓: P < 0.0001 Li et al., 2017c
Tumor suppression ↓: MCF7, T47D, MDA-MB-231HM ↑: BT549 MCF10A Both 25 (BC)/25 (ANT) ↓ (P-value was not provided) Li et al., 2017b

DANCR is considered as a powerful biomarker not only in discriminating cancer patients from healthy people or patients with benign diseases but also in helping to predict the prognosis for cancer patients. Moreover, the combination of DANCR and other traditional biomarkers may enhance diagnostic efficiency. For cancer treatment, DANCR may be a promising target due to its essential role in cancers. Though DANCR was a promising biomarker and therapeutic target in cancer, more comprehensive and systematic clinical studies and more extensive sample tests are needed to further explore these complex issues. Further studies in DANCR mechanistic investigations and clinical application are still needed. Only after the mechanisms of DANCR in specific cancers have been elucidated can it likely be used for therapeutic purposes.

 Author Contributions

JY, XiZ, and XF conceived the project and supervised the writing. MW and JG wrote the draft of the review. XuZ and XF provided funds and assisted with preparation of the manuscript. All authors are involved in the revision and approved the final version of the manuscript.

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Funding

This work was supported by the National Natural Science Foundation of China (81972310), the Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province (2019GSZDSYS01, 2019GSZDSYS02), the Six Talent Peaks Project in Jiangsu Province (2019-YY-188), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Postgraduate Research Innovation Program of Jiangsu Province (KYCX21-3405), and the Major Science and Technology Projects of Changzhou Municipal Committee of Health and Family Planning (ZD201917).

Some elements of Figure 1 were modified from Servier Medical Art (http://smart.servier.com/). We would like to acknowledge them for providing free academic licenses (https://creativecommons.org/licenses/by/3.0/).

 References Abdullah M. I. Junit S. M. Ng K. L. Jayapalan J. J. Karikalan B. Hashim O. H. (2019). Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int. J. Med. Sci. 16 450–460. 10.7150/ijms.29935 30911279 Anastasiadou E. Jacob L. S. Slack F. J. (2018). Non-coding RNA networks in cancer. Nat. Rev. Cancer 18 5–18. 10.1038/nrc.2017.99 29170536 Arnold M. Sierra M. S. Laversanne M. Soerjomataram I. Jemal A. Bray F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut 66 683–691. 10.1136/gutjnl-2015-310912 26818619 Bahreini F. Saidijam M. Mousivand Z. Najafi R. Afshar S. (2021). Assessment of lncRNA DANCR, miR-145-5p and NRAS axis as biomarkers for the diagnosis of colorectal cancer. Mol. Biol. Rep. 48 3541–3547. 10.1007/s11033-021-06373-2 33956301 Bai Y. Zhang G. Chu H. Li P. Li J. (2019). The positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates malignancy in non-small cell lung cancer. Am. J. Cancer Res. 9 270–284. Bhanvadia S. K. (2018). Bladder cancer survivorship. Curr. Urol. Rep. 19:111. 10.1007/s11934-018-0860-6 30414013 Bi Y. Guo S. Xu X. Kong P. Cui H. Yan T. (2020). Decreased ZNF750 promotes angiogenesis in a paracrine manner via activating DANCR/miR-4707-3p/FOXC2 axis in esophageal squamous cell carcinoma. Cell Death Dis. 11:296. 10.1038/s41419-020-2492-2 32341351 Boldrup L. Gu X. Coates P. J. Norberg-Spaak L. Fahraeus R. Laurell G. (2017). Gene expression changes in tumor free tongue tissue adjacent to tongue squamous cell carcinoma. Oncotarget 8 19389–19402. 10.18632/oncotarget.14288 28038473 Cai C. Zhang H. Zhu Y. Zheng P. Xu Y. Sun J. (2019). Serum exosomal long noncoding RNA pcsk2-2:1 as a potential novel diagnostic biomarker for gastric cancer. Onco Targets Ther. 12 10035–10041. 10.2147/ott.S229033 31819499 Cao L. Jin H. Zheng Y. Mao Y. Fu Z. Li X. (2019). DANCR-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway. Cancer Sci. 110 913–925. 10.1111/cas.13921 30582654 Chen L. Song Z. Huang S. Wang R. Qin W. Guo J. (2016). lncRNA DANCR suppresses odontoblast-like differentiation of human dental pulp cells by inhibiting wnt/beta-catenin pathway. Cell Tissue Res. 364 309–318. 10.1007/s00441-015-2333-2 26646542 Chen L. Song Z. Wu J. Huang Q. Shen Z. Wei X. (2020). LncRNA DANCR sponges miR-216a to inhibit odontoblast differentiation through upregulating c-Cbl. Exp. Cell Res. 387:111751. 10.1016/j.yexcr.2019.111751 31805275 Chen Y. R. Wu Y. S. Wang W. S. Zhang J. S. Wu Q. G. (2020). Upregulation of lncRNA DANCR functions as an oncogenic role in non-small lung cancer by regulating miR-214-5p/CIZ1 axis. Eur. Rev. Med. Pharmacol. Sci. 24 2539–2547. 10.26355/eurrev_202003_20521 Chen Y. Zhang L. Liu W. X. Wang K. (2018). VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cell. Mol. Biol. Lett. 23:2. 10.1186/s11658-017-0058-9 29308068 Chen Z. Chen X. Xie R. Huang M. Dong W. Han J. (2019). DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression. Mol. Ther. 27 326–341. 10.1016/j.ymthe.2018.12.015 30660488 Cheng C. Dong Y. Ru X. Xia Y. Ji Y. (2020). LncRNA ANCR promotes glioma cells invasion, migration, proliferation and inhibits apoptosis via interacting with EZH2 and repressing PTEN expression. Cancer Gene Ther. 28 1025–1034. 10.1038/s41417-020-00263-8 33293663 Chua M. L. K. Wee J. T. S. Hui E. P. Chan A. T. C. (2016). Nasopharyngeal carcinoma. Lancet 387 1012–1024. 10.1016/s0140-6736(15)00055-0 Cortez A. J. Tudrej P. Kujawa K. A. Lisowska K. M. (2018). Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol. 81 17–38. 10.1007/s00280-017-3501-8 29249039 Costa R. L. B. Han H. S. Gradishar W. J. (2018). Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res. Treat. 169 397–406. 10.1007/s10549-018-4697-y 29417298 Cui P. H. Li Z. Y. Li D. H. Han S. Y. Zhang Y. J. (2020). SP1-induced lncRNA DANCR contributes to proliferation and invasion of ovarian cancer. Kaohsiung J. Med. Sci. 37 371–378. 10.1002/kjm2.12316 33089960 Deng H. Zhu B. Dong Z. Jiang H. Zhao X. Wu S. (2021). miR-214-5p targeted by LncRNA DANCR mediates TGF-β signaling pathway to accelerate proliferation, migration and inhibit apoptosis of prostate cancer cells. Am. J. Transl. Res. 13 2224–2240. Ding S. Chen X. Shen K. (2020). Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun. 40 329–344. 10.1002/cac2.12078 32654419 Domanska U. M. Timmer-Bosscha H. Nagengast W. B. Oude Munnink T. H. Kruizinga R. C. Ananias H. J. (2012). CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14 709–718. 10.1593/neo.12324 22952424 Duan J. Wu Y. Liu J. Zhang J. Fu Z. Feng T. (2019). Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J. Hepatocell. Carcinoma 6 151–166. 10.2147/jhc.S224849 31696097 Encinas de la Iglesia J. Corral de la Calle M. A. Fernandez Perez G. C. Ruano Perez R. Alvarez Delgado A. (2016). Esophageal cancer: anatomic particularities, staging, and imaging techniques. Radiologia 58 352–365. 10.1016/j.rx.2016.06.004 27469407 Fabian M. R. Sonenberg N. Filipowicz W. (2010). Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79 351–379. 10.1146/annurev-biochem-060308-103103 20533884 Fan T. M. Roberts R. D. Lizardo M. M. (2020). Understanding and modeling metastasis biology to improve therapeutic strategies for combating osteosarcoma progression. Front. Oncol. 10:13. 10.3389/fonc.2020.00013 32082995 Feng L. Lin T. Che H. Wang X. (2020). Long noncoding RNA DANCR knockdown inhibits proliferation, migration and invasion of glioma by regulating miR-135a-5p/BMI1. Cancer Cell Int. 20:53. 10.1186/s12935-020-1123-4 32099526 Ferretti V. A. León I. E. (2021). Long non-coding RNAs in cisplatin resistance in osteosarcoma. Curr. Treat. Options Oncol. 22:41. 10.1007/s11864-021-00839-y 33745006 Fico A. Fiorenzano A. Pascale E. Patriarca E. J. Minchiotti G. (2019). Long non-coding RNA in stem cell pluripotency and lineage commitment: functions and evolutionary conservation. Cell. Mol. Life Sciences 76 1459–1471. 10.1007/s00018-018-3000-z 30607432 Forner A. Reig M. Bruix J. (2018). Hepatocellular carcinoma. Lancet 391 1301–1314. 10.1016/s0140-6736(18)30010-2 Gan L. Chen S. Wang Y. Watahiki A. Bohrer L. Sun Z. (2009). Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 69 8386–8394. 10.1158/0008-5472.Can-09-1504 19826044 Goyal L. Kongpetch S. Crolley V. E. Bridgewater J. (2021). Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat. Rev. 95:102170. 10.1016/j.ctrv.2021.102170 33735689 Grayson M. (2017). Bladder cancer. Nature 551:S33. 10.1038/551S33a 29117156 Guo D. Li Y. Chen Y. Zhang D. Wang X. Lu G. (2019). DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway. Cell Prolif. 52:e12628. 10.1111/cpr.12628 31038266 Guo L. Gu J. Hou S. Liu D. Zhou M. Hua T. (2019). Long non-coding RNA DANCR promotes the progression of non-small-cell lung cancer by inhibiting p21 expression. Onco Targets Ther. 12 135–146. 10.2147/OTT.S186607 30613152 Guo Q. Jing F. J. Xu W. Li X. Li X. Sun J. L. (2019). Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-kappaB axis. Aging 12 80–105. 10.18632/aging.102598 31895687 Hao Y. P. Qiu J. H. Zhang D. B. Yu C. G. (2017). Long non-coding RNA DANCR, a prognostic indicator, promotes cell growth and tumorigenicity in gastric cancer. Tumour Biol. 39:1010428317699798. 10.1177/1010428317699798 28618943 Hao Y. Zhao H. Jin X. He P. Zhang J. Dong Q. (2019). Long noncoding RNA DANCR promotes nasopharyngeal carcinoma cell proliferation and migration. Mol. Med. Rep. 19 2883–2889. 10.3892/mmr.2019.9906 30720067 Herbst R. S. Heymach J. V. Lippman S. M. (2008). Lung cancer. N. Engl. J. Med. 359 1367–1380. 10.1056/NEJMra0802714 18815398 Hou X. Wen J. Ren Z. Zhang G. (2017). Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer. Oncotarget 8 43571–43578. 10.18632/oncotarget.16721 28388588 Hu C. Han Y. Zhu G. Li G. Wu X. (2021). Krüppel-like factor 5-induced overexpression of long non-coding RNA DANCR promotes the progression of cervical cancer via repressing microRNA-145-3p to target ZEB1. Cell Cycle 20 1441–1454. 10.1080/15384101.2021.1941625 34233586 Hu H. Wang Y. Li Z. Zhu Y. Zhang W. Wang D. (2017). Overexpression of suppressor of zest 12 is associated with cervical node metastasis and unfavorable prognosis in tongue squamous cell carcinoma. Cancer Cell Int. 17:26. 10.1186/s12935-017-0395-9 28228691 Hu X. Peng W. X. Zhou H. Jiang J. Zhou X. Huang D. (2020). IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader. Cell Death Differ. 27 1782–1794. 10.1038/s41418-019-0461-z 31804607 Huang F. L. Yu S. J. (2018). Esophageal cancer: risk factors, genetic association, and treatment. Asian J. Surg. 41 210–215. 10.1016/j.asjsur.2016.10.005 27986415 Huang P. Qi B. Yao H. Zhang L. Li Y. Li Q. (2020). Knockdown of DANCR suppressed the biological behaviors of ovarian cancer cells treated with transforming growth factor-β (TGF-β) by sponging MiR-214. Med. Sci. Monit. 26:e922760. 10.12659/msm.922760 32417846 Huang Y. F. Zhang Y. Fu X. (2021). Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225-3p/ErbB2 signal. Eur. Rev. Med. Pharmacol. Sci. 25 758–769. 10.26355/eurrev_202101_24637 Iyer M. K. Niknafs Y. S. Malik R. Singhal U. Sahu A. Hosono Y. (2015). The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 47 199–208. 10.1038/ng.3192 25599403 Jegerlehner S. Bulliard J. L. Aujesky D. Rodondi N. Germann S. Konzelmann I. (2017). Overdiagnosis and overtreatment of thyroid cancer: a population-based temporal trend study. PLoS One 12:e0179387. 10.1371/journal.pone.0179387 28614405 Jia H. Liang K. Liu G. Zhang Z. Shi Y. Liang H. (2020). lncRNA DANCR promotes proliferation and metastasis of breast cancer cells through sponging miR-4319 and upregulating VAPB. Cancer Biother. Radiopharm. 10.1089/cbr.2020.3675 [Epub ahead of print]. 32818383 Jia J. Li F. Tang X. S. Xu S. Gao Y. Shi Q. (2016). Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3. Oncotarget 7 37868–37881. 10.18632/oncotarget.9350 27191265 Jiang J. Huang H. (2010). Targeting the androgen receptor by taxol in castration-resistant prostate cancer. Mol. Cell. Pharmacol. 2 1–5. Jiang N. Wang X. Xie X. Liao Y. Liu N. Liu J. (2017). lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition. Cancer Lett. 405 46–55. 10.1016/j.canlet.2017.06.009 28642170 Jin K.-T. Yao J.-Y. Fang X.-L. Di H. Ma Y.-Y. (2020). Roles of lncRNAs in cancer: focusing on angiogenesis. Life Sci. 252:117647. 10.1016/j.lfs.2020.117647 32275935 Jin L. Fu H. Quan J. Pan X. He T. Hu J. (2017). Overexpression of long non-coding RNA differentiation antagonizing non-protein coding RNA inhibits the proliferation, migration and invasion and promotes apoptosis of renal cell carcinoma. Mol. Med. Rep. 16 4463–4468. 10.3892/mmr.2017.7135 28765964 Kahn B. Collazo J. Kyprianou N. (2014). Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int. J. Biol. Sci. 10 588–595. 10.7150/ijbs.8671 24948871 Kanzaki R. Pietras K. (2020). Heterogeneity of cancer-associated fibroblasts: opportunities for precision medicine. Cancer Sci. 111 2708–2717. 10.1111/cas.14537 32573845 Kessler T. A. (2017). Cervical cancer: prevention and early detection. Semin. Oncol. Nurs. 33 172–183. 10.1016/j.soncn.2017.02.005 28343836 Kretz M. Webster D. E. Flockhart R. J. Lee C. S. Zehnder A. Lopez-Pajares V. (2012). Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev. 26 338–343. 10.1101/gad.182121.111 22302877 Le Bras G. F. Farooq M. H. Falk G. W. Andl C. D. (2016). Esophageal cancer: the latest on chemoprevention and state of the art therapies. Pharmacol. Res. 113(Pt A) 236–244. 10.1016/j.phrs.2016.08.021 27565381 Li J. Zhou L. (2018). Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/beta-catenin signaling. Biomed. Pharmacother. 102 602–607. 10.1016/j.biopha.2018.03.116 29602127 Li Q. Jiang Y. Zhong G. Lu Y. Song T. Zhang Y. (2020). Long noncoding RNA DANCR regulates cell proliferation by stabilizing SOX2 mRNA in nasopharyngeal carcinoma. Am. J. Pathol. 190 2343–2354. 10.1016/j.ajpath.2020.09.005 32971057 Li Z. Hou P. Fan D. Dong M. Ma M. Li H. (2017c). The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 24 59–71. 10.1038/cdd.2016.95 27716745 Li Z. Dong M. Fan D. Hou P. Li H. Liu L. (2017b). LncRNA ANCR down-regulation promotes TGF-beta-induced EMT and metastasis in breast cancer. Oncotarget 8 67329–67343. 10.18632/oncotarget.18622 28978036 Li Q. Li H. Zhang L. Zhang C. Yan W. Wang C. (2017a). Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer. Oncotarget 8 46136–46144. 10.18632/oncotarget.17556 28545026 Lian J. Zhang H. Wei F. Li Q. Lu Y. Yu B. (2020). Long non-coding RNA DANCR promotes colorectal tumor growth by binding to lysine acetyltransferase 6A. Cell. Signal. 67:109502. 10.1016/j.cellsig.2019.109502 31863900 Liang H. Zhang C. Guan H. Liu J. Cui Y. (2019). LncRNA DANCR promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p. J. Cell. Physiol. 234 7266–7278. 10.1002/jcp.27484 30362591 Liao Z. Nie H. Wang Y. Luo J. Zhou J. Ou C. (2021). The emerging landscape of long non-coding RNAs in colorectal cancer metastasis. Front. Oncol. 11:641343. 10.3389/fonc.2021.641343 33718238 Lin T. H. Izumi K. Lee S. O. Lin W. J. Yeh S. Chang C. (2013). Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 4:e764. 10.1038/cddis.2013.270 23928703 Lin X. Yang F. Qi X. Li Q. Wang D. Yi T. (2019). LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145. Mol. Carcinog. 58 2286–2296. 10.1002/mc.23117 31545000 Litwin M. S. Tan H. J. (2017). The diagnosis and treatment of prostate cancer: a review. JAMA 317 2532–2542. 10.1001/jama.2017.7248 28655021 Liu B. Zhao H. Zhang L. Shi X. (2019). Silencing of long-non-coding RNA ANCR suppresses the migration and invasion of osteosarcoma cells by activating the p38MAPK signalling pathway. BMC Cancer 19:1112. 10.1186/s12885-019-6335-4 31727012 Liu Y. Chen L. Yuan H. Guo S. Wu G. (2020a). LncRNA DANCR promotes sorafenib resistance via activation of IL-6/STAT3 signaling in hepatocellular carcinoma cells. Onco Targets Ther. 13 1145–1157. 10.2147/ott.S229957 32103983 Liu Y. Li J. Yue B. Liang L. Zhang S. Chen Y. (2020b). Long non-coding RNA DANCR regulate MLL3 and thereby it determines the progression of pancreatic cancer. J. BUON 25 1954–1959. Liu Y. Zhang M. Liang L. Li J. Chen Y. X. (2015). Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. Int. J. Clin. Exp. Pathol. 8 11480–11484. Llovet J. M. Ricci S. Mazzaferro V. Hilgard P. Gane E. Blanc J.-F. (2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 378–390. 10.1056/NEJMoa0708857 18650514 Lu J. Chen Z. Zhao H. Dong H. Zhu L. Zhang Y. (2020). ABAT and ALDH6A1, regulated by transcription factor HNF4A, suppress tumorigenic capability in clear cell renal cell carcinoma. J. Transl. Med. 18:101. 10.1186/s12967-020-02268-1 32093682 Lu Q. C. Rui Z. H. Guo Z. L. Xie W. Shan S. Ren T. (2018). LncRNA-DANCR contributes to lung adenocarcinoma progression by sponging miR-496 to modulate mTOR expression. J. Cell. Mol. Med. 22 1527–1537. 10.1111/jcmm.13420 29266795 Lu W. Huang Z. Wang J. Liu H. (2021). Long non-coding RNA DANCR accelerates colorectal cancer progression via regulating the miR-185-5p/HMGA2 axis. J. Biochem. mvab011. 10.1093/jb/mvab011 [Epub ahead of print]. 33481014 Lu Y. Hu Z. Mangala L. S. Stine Z. E. Hu X. Jiang D. (2018). MYC targeted long noncoding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Res. 78 64–74. 10.1158/0008-5472.CAN-17-0815 29180471 Luo Y. Wang Q. Teng L. Zhang J. Song J. Bo W. (2019). LncRNA DANCR promotes proliferation and metastasis in pancreatic cancer by regulating miRNA-33b. FEBS Open Bio 10 18–27. 10.1002/2211-5463.12732 31515968 Ma X. Wang X. Yang C. Wang Z. Han B. Wu L. (2016). DANCR acts as a diagnostic biomarker and promotes tumor growth and metastasis in hepatocellular carcinoma. Anticancer Res. 36 6389–6398. 10.21873/anticanres.11236 27919960 Ma X. Yuan Y. Lu J. Li M. Yu Y. Liu J. (2021). Long noncoding RNA ANCR promotes migration, invasion, EMT progress and stemness of nasopharyngeal carcinoma cells via the miR-4731-5p/NMT1 axis. Pathol. Res. Pract. 224:153540. 10.1016/j.prp.2021.153540 34333213 Ma X. Zhou J. Liu J. Wu G. Yu Y. Zhu H. (2018). LncRNA ANCR promotes proliferation and radiation resistance of nasopharyngeal carcinoma by inhibiting PTEN expression. Onco Targets Ther. 11 8399–8408. 10.2147/ott.S182573 30568463 Ma Y. Fan B. Ren Z. Liu B. Wang Y. (2019). Long noncoding RNA DANCR contributes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway. Onco Targets Ther. 12 5485–5497. 10.2147/OTT.S197009 31371987 Ma Y. Zhou G. Li M. Hu D. Zhang L. Liu P. (2018). Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-kappaB signaling pathway. Neurochem. Int. 118 233–241. 10.1016/j.neuint.2018.03.011 29572052 Magnan S. Zarychanski R. Pilote L. Bernier L. Shemilt M. Vigneault E. (2015). Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 1 1261–1269. 10.1001/jamaoncol.2015.2895 26378418 Malakootian M. Mirzadeh Azad F. Fouani Y. Taheri Bajgan E. Saberi H. Mowla S. J. (2018). Anti-differentiation non-coding RNA, ANCR, is differentially expressed in different types of brain tumors. J. Neuro Oncol. 138 261–270. 10.1007/s11060-018-2809-5 29476310 Matulonis U. A. Sood A. K. Fallowfield L. Howitt B. E. Sehouli J. Karlan B. Y. (2016). Ovarian cancer. Nat. Rev. Dis. Primers 2:16061. 10.1038/nrdp.2016.61 27558151 Misawa A. Takayama K. I. Inoue S. (2017). Long non-coding RNAs and prostate cancer. Cancer Sci. 108 2107–2114. 10.1111/cas.13352 28796922 Moore A. Donahue T. (2019). Pancreatic cancer. JAMA 322:1426. 10.1001/jama.2019.14699 31593274 Nuhn P. De Bono J. S. Fizazi K. Freedland S. J. Grilli M. Kantoff P. W. (2019). Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. 75 88–99. 10.1016/j.eururo.2018.03.028 29673712 Pan L. Liang W. Gu J. Zang X. Huang Z. Shi H. (2018). Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells. Oncotarget 9 1915–1930. 10.18632/oncotarget.23019 29416741 Pan Z. Wu C. Li Y. Li H. An Y. Wang G. (2020). LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p. Biomed. Pharmacother. 122:109707. 10.1016/j.biopha.2019.109707 31918278 Pei C. L. Fei K. L. Yuan X. Y. Gong X. J. (2019). LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1. Eur. Rev. Med. Pharmacol. Sci. 23 10657–10663. 10.26355/eurrev_201912_19763 Ping Q. Shi Y. Yang M. Li H. Zhong Y. Li J. (2021). LncRNA DANCR regulates lymphatic metastasis of bladder cancer via the miR-335/VEGF-C axis. Transl. Androl. Urol. 10 1743–1753. 10.21037/tau-21-226 33968662 Richters A. Aben K. K. H. Kiemeney L. (2019). The global burden of urinary bladder cancer: an update. World J. Urol. 38 1895–1904. 10.1007/s00345-019-02984-4 31676912 Ritter J. Bielack S. S. (2010). Osteosarcoma. Ann. Oncol. 21(Suppl. 7) vii320–vii325. 10.1093/annonc/mdq276 20943636 Rizvi S. Khan S. A. Hallemeier C. L. Kelley R. K. Gores G. J. (2018). Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15 95–111. 10.1038/nrclinonc.2017.157 28994423 Salmena L. Poliseno L. Tay Y. Kats L. Pandolfi P. P. (2011). A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146 353–358. 10.1016/j.cell.2011.07.014 21802130 Semenza G. L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 721–732. 10.1038/nrc1187 13130303 Serra O. Galan M. Ginesta M. M. Calvo M. Sala N. Salazar R. (2019). Comparison and applicability of molecular classifications for gastric cancer. Cancer Treat. Rev. 77 29–34. 10.1016/j.ctrv.2019.05.005 31195213 Sha S. Yuan D. Liu Y. Han B. Zhong N. (2017). Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression. Biol. Open 6 1310–1316. 10.1242/bio.023135 28760736 Shan Y. You B. Shi S. Shi W. Zhang Z. Zhang Q. (2018). Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9:382. 10.1038/s41419-018-0425-0 29515112 Shen X. Xue Y. Cong H. Wang X. Fan Z. Cui X. (2020). Circulating lncRNA DANCR as a potential auxillary biomarker for the diagnosis and prognostic prediction of colorectal cancer. Biosci. Rep. 40:BSR20191481. 10.1042/bsr20191481 32159208 Shi H. Li K. Feng J. Liu G. Feng Y. Zhang X. (2020). LncRNA-DANCR interferes with miR-125b-5p/HK2 axis to desensitize colon cancer cells to cisplatin vis activating anaerobic glycolysis. Front. Oncol. 10:1034. 10.3389/fonc.2020.01034 32766131 Shi H. Shi J. Zhang Y. Guan C. Zhu J. Wang F. (2018). Long non-coding RNA DANCR promotes cell proliferation, migration, invasion and resistance to apoptosis in esophageal cancer. J. Thorac. Dis. 10 2573–2582. 10.21037/jtd.2018.04.109 29997918 Siegel R. L. Miller K. D. Fedewa S. A. Ahnen D. J. Meester R. G. S. Barzi A. (2017). Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67 177–193. 10.3322/caac.21395 28248415 Siegel R. L. Miller K. D. Fuchs H. E. Jemal A. (2021). Cancer statistics, 2021. CA Cancer J. Clin. 71 7–33. 10.3322/caac.21654 33433946 Siegel R. L. Miller K. D. Jemal A. (2019). Cancer statistics, 2019. CA Cancer J. Clin. 69 7–34. 10.3322/caac.21551 30620402 Song X. Z. Xu X. J. Ren X. N. Ruan X. X. Wang Y. L. Yao T. T. (2020). LncRNA ANCR suppresses the progression of hepatocellular carcinoma through the inhibition of Wnt/β-catenin signaling pathway. Onco Targets Ther. 13 8907–8917. 10.2147/ott.S260556 32982283 Sturm D. Pfister S. M. Jones D. T. W. (2017). Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J. Clin. Oncol. 35 2370–2377. 10.1200/jco.2017.73.0242 28640698 Sun W. Zu S. Shao G. Wang W. Gong F. (2021). Long non-coding DANCR targets miR-185-5p to upregulate LIM and SH3 protein 1 promoting prostate cancer via the FAK/PI3K/AKT/GSK3β/snail pathway. J. Gene Med. 23:e3344. 10.1002/jgm.3344 33885171 Sun Y. Cao B. Zhou J. (2020). Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells. BMC Cancer 20:434. 10.1186/s12885-020-06856-8 32423468 Ta W. Zhang Y. Zhang S. Sun P. (2020). LncRNA ANCR downregulates hypoxiainducible factor 1alpha and inhibits the growth of HPV negative cervical squamous cell carcinoma under hypoxic conditions. Mol. Med. Rep. 21 413–419. 10.3892/mmr.2019.10792 31746351 Tang J. Zhong G. Zhang H. Yu B. Wei F. Luo L. (2018). LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA. Cell Death Dis. 9:1167. 10.1038/s41419-018-1220-7 30518934 Tang Y. Cao G. Zhao G. Wang C. Qin Q. (2020). LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer. Invest. New Drugs 38 714–721. 10.1007/s10637-019-00798-0 31267381 Tao W. Wang C. Zhu B. Zhang G. Pang D. (2019). LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression. Biosci. Rep. 39:BSR20181618. 10.1042/BSR20181618 30910842 Tian W. Lei N. Guo R. Yuan Z. Chang L. (2020). Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/beta-catenin signaling pathway. Cancer Cell Int. 20:61. 10.1186/s12935-020-1139-9 32123519 Wang J. Pu J. Zhang Y. Yao T. Luo Z. Li W. (2019). DANCR contributed to hepatocellular carcinoma malignancy via sponging miR-216a-5p and modulating KLF12. J. Cell. Physiol. 234 9408–9416. 10.1002/jcp.27625 30430564 Wang N. Zhang C. Wang W. Liu J. Yu Y. Li Y. (2019). Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma. Cell Death Dis. 10:585. 10.1038/s41419-019-1810-z 31383847 Wang S. Jiang M. (2018). The long non-coding RNA-DANCR exerts oncogenic functions in non-small cell lung cancer via miR-758-3p. Biomed. Pharmacother. 103 94–100. 10.1016/j.biopha.2018.03.053 29635134 Wang Y. Lu Z. Wang N. Feng J. Zhang J. Luan L. (2018b). Long noncoding RNA DANCR promotes colorectal cancer proliferation and metastasis via miR-577 sponging. Exp. Mol. Med. 50:57. 10.1038/s12276-018-0082-5 29717105 Wang Y. Zeng X. Wang N. Zhao W. Zhang X. Teng S. (2018c). Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol. Cancer 17:89. 10.1186/s12943-018-0837-6 29753317 Wang S. Lan F. Xia Y. (2018a). lncRA ANCR inhibits non-small cell lung cancer cell migration and invasion by inactivating TGF-beta pathway. Med. Sci. Monit. 24 6002–6009. 10.12659/msm.911492 30154397 Wang S. C. Li C. Y. Chang W. T. Cheng W. C. Yen C. H. Tu W. Y. (2020). Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. Liver Int. 41 956–968. 10.1111/liv.14772 33346937 Wang W. Li Y. Ma Q. Yan H. Su W. (2019). Differentiation antagonizing non-protein coding RNA modulates the proliferation, migration, and angiogenesis of glioma cells by targeting the miR-216a/LGR5 axis and the PI3K/AKT signaling pathway. Onco Targets Ther. 12 2439–2449. 10.2147/ott.S196851 31114219 Wang X. Cheng M. L. Gong Y. Ma W. J. Li B. Jiang Y. Z. (2020). LncRNA DANCR promotes ATG7 expression to accelerate hepatocellular carcinoma cell proliferation and autophagy by sponging miR-222-3p. Eur. Rev. Med. Pharmacol. Sci. 24 8778–8787. 10.26355/eurrev_202009_22816 Wang X. Qi Y. Kong X. Zhai J. Li Y. Song Y. (2019). Immunological therapy: a novel thriving area for triple-negative breast cancer treatment. Cancer Lett. 442 409–428. 10.1016/j.canlet.2018.10.042 30419345 Wang Z. Huang Y. Tan L. (2020). Downregulation of lncRNA DANCR promotes osteogenic differentiation of periodontal ligament stem cells. BMC Dev. Biol. 20:2. 10.1186/s12861-019-0206-8 31931700 Wen X. Liu X. Mao Y. P. Yang X. J. Wang Y. Q. Zhang P. P. (2018). Long non-coding RNA DANCR stabilizes HIF-1alpha and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma. Theranostics 8 5676–5689. 10.7150/thno.28538 30555573 Wen Z. Lian L. Ding H. Hu Y. Xiao Z. Xiong K. (2020). LncRNA ANCR promotes hepatocellular carcinoma metastasis through upregulating HNRNPA1 expression. RNA Biol. 17 381–394. 10.1080/15476286.2019.1708547 31868085 Weng W. Di S. Xing S. Sun Z. Shen Z. Dou X. (2021). Long non-coding RNA DANCR modulates osteogenic differentiation by regulating the miR-1301-3p/PROX1 axis. Mol. Cell. Biochem. 476 2503–2512. 10.1007/s11010-021-04074-9 33629241 Wu G. Zhou H. Li D. Zhi Y. Liu Y. Li J. (2020). LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis. Exp. Cell Res. 396:112331. 10.1016/j.yexcr.2020.112331 33058834 Xie C. Guo Y. Lou S. (2020). LncRNA ANCR promotes invasion and migration of gastric cancer by regulating FoxO1 expression to inhibit macrophage M1 polarization. Dig. Dis. Sci. 65 2863–2872. 10.1007/s10620-019-06019-1 31894487 Xiong M. Wu M. Dan P. Huang W. Chen Z. Ke H. (2021). LncRNA DANCR represses Doxorubicin-induced apoptosis through stabilizing MALAT1 expression in colorectal cancer cells. Cell Death Dis. 12:24. 10.1038/s41419-020-03318-8 33414433 Xu D. Yu J. Gao G. Lu G. Zhang Y. Ma P. (2018). LncRNA DANCR functions as a competing endogenous RNA to regulate RAB1A expression by sponging miR-634 in glioma. Biosci. Rep. 38:BSR20171664. 10.1042/BSR20171664 29301870 Xu Y. D. Shang J. Li M. Zhang Y. Y. (2019). LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 23 2794–2802. 10.26355/eurrev_201904_17554 Xu Y. Qiu M. Shen M. Dong S. Ye G. Shi X. (2021). The emerging regulatory roles of long non-coding RNAs implicated in cancer metabolism. Mol. Ther. 29 2209–2218. 10.1016/j.ymthe.2021.03.017 33775912 Yan X. Hu Z. Feng Y. Hu X. Yuan J. Zhao S. D. (2015). Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell 28 529–540. 10.1016/j.ccell.2015.09.006 26461095 Yang J. X. Sun Y. Gao L. Meng Q. Yang B. Y. (2018). Long non-coding RNA DANCR facilitates glioma malignancy by sponging miR-33a-5p. Neoplasma 65 790–798. 10.4149/neo_2018_170724N498 Yang L. Jiang M. N. Liu Y. Wu C. Q. Liu H. (2020). Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression. Tumori 300891620977010. 10.1177/0300891620977010 [Epub ahead of print]. 33272103 Yang Z. Y. Yang F. Zhang Y. L. Liu B. Wang M. Hong X. (2017). LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression. Cancer Biomark. 18 95–104. 10.3233/cbm-161715 27983539 Yao Z. Chen Q. Ni Z. Zhou L. Wang Y. Yang Y. (2019). Long non-coding RNA differentiation antagonizing nonprotein coding RNA (DANCR) promotes proliferation and invasion of pancreatic cancer by sponging miR-214-5p to regulate E2F2 expression. Med. Sci. Monit. 25 4544–4552. 10.12659/MSM.916960 31213582 Yin Z. Zhang X. Wang Y. Wang P. Yuan Z. (2017). The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients. Onco Targets Ther. 10 5677–5683. 10.2147/ott.S150035 29225474 Yu J. E. Ju J. A. Musacchio N. Mathias T. J. Vitolo M. I. (2020). Long noncoding RNA DANCR activates Wnt/β-catenin signaling through MiR-216a inhibition in non-small cell lung cancer. Biomolecules 10:1646. 10.3390/biom10121646 33302540 Yuan S. X. Wang J. Yang F. Tao Q. F. Zhang J. Wang L. L. (2016). Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology 63 499–511. 10.1002/hep.27893 25964079 Zhan Y. Chen Z. Li Y. He A. He S. Gong Y. (2018). Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J. Exp. Clin. Cancer Res. 37:273. 10.1186/s13046-018-0921-1 30419948 Zhang C. Wang L. Yang J. Fu Y. Li H. Xie L. (2019). MicroRNA-33a-5p suppresses esophageal squamous cell carcinoma progression via regulation of lncRNA DANCR and ZEB1. Eur. J. Pharmacol. 861:172590. 10.1016/j.ejphar.2019.172590 31401160 Zhang F. Peng H. (2017). LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27. J. Orthop. Surg. Res. 12:103. 10.1186/s13018-017-0599-7 28679390 Zhang H. Cai Y. Zheng L. Zhang Z. Lin X. Jiang N. (2018). Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression. J. Cell. Physiol. 233 6638–6648. 10.1002/jcp.26425 29319165 Zhang J. Jin X. Zhou C. Zhao H. He P. Hao Y. (2020). Resveratrol suppresses human nasopharyngeal carcinoma cell growth via inhibiting differentiation antagonizing non-protein coding RNA (DANCR) expression. Med. Sci. Monit. 26:e923622. 10.12659/msm.923622 32683392 Zhang J. Tao Z. Wang Y. (2018). Long non-coding RNA DANCR regulates the proliferation and osteogenic differentiation of human bone-derived marrow mesenchymal stem cells via the p38 MAPK pathway. Int. J. Mol. Med. 41 213–219. 10.3892/ijmm.2017.3215 29115577 Zhang K. Lv J. Peng X. Liu J. Li C. Li J. (2019). Down-regulation of DANCR acts as a potential biomarker for papillary thyroid cancer diagnosis. Biosci. Rep. 39:BSR20181616. 10.1042/BSR20181616 30910839 Zhang K. J. Tan X. L. Guo L. (2020). The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription. Mol. Oncol. 14 309–328. 10.1002/1878-0261.12622 31860165 Zhang L. Xu Z. Xu X. Zhang B. Wu H. Wang M. (2014). SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene 33 5491–5500. 10.1038/onc.2013.495 24276240 Zhang L. Yang C. Chen S. Wang G. Shi B. Tao X. (2017). Long noncoding RNA DANCR is a positive regulator of proliferation and chondrogenic differentiation in human synovium-derived stem cells. DNA Cell Biol. 36 136–142. 10.1089/dna.2016.3544 27982693 Zhang N. Jiang W. (2019). Long noncoding RNA DANCR promotes HMGA2mediated invasion in lung adenocarcinoma cells. Oncol. Rep. 41 1083–1090. 10.3892/or.2018.6897 30535487 Zhang W. Li J. Z. Tai Q. Y. Tang J. J. Huang Y. H. Gao S. B. (2020). LncRNA DANCR regulates osteosarcoma migration and invasion by targeting miR-149/MSI2 axis. Eur. Rev. Med. Pharmacol. Sci. 24 6551–6560. 10.26355/eurrev_202006_21639 Zhang X. Chen J. Meng Q. Li D. Hu F. Z. Zhu Y. Q. (2020). The protective effects of long non-coding RNA-ANCR on arterial calcification. J. Bone Miner. Metab. 38 421–431. 10.1007/s00774-019-01076-y 31974677 Zhang X. Yang J. Bian Z. Shi D. Cao Z. (2019). Long noncoding RNA DANCR promotes nasopharyngeal carcinoma progression by interacting with STAT3, enhancing IL-6/JAK1/STAT3 signaling. Biomed. Pharmacother. 113:108713. 10.1016/j.biopha.2019.108713 30849642 Zhang X. H. Li B. F. Ding J. Shi L. Ren H. M. Liu K. (2020). LncRNA DANCR-miR-758-3p-PAX6 molecular network regulates apoptosis and autophagy of breast cancer cells. Cancer Manag. Res. 12 4073–4084. 10.2147/cmar.S254069 32581581 Zhao H. F. Zhang Z. C. Shi B. K. Jiang X. Z. (2019). DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer. Eur. Rev. Med. Pharmacol. Sci. 23 6849–6857. 10.26355/eurrev_201908_18724 Zhen Q. Gao L. N. Wang R. F. Chu W. W. Zhang Y. X. Zhao X. J. (2018). LncRNA DANCR promotes lung cancer by sequestering miR-216a. Cancer Control 25:1073274818769849. 10.1177/1073274818769849 29651883 Zheng Y. Zheng B. Meng X. Yan Y. He J. Liu Y. (2019). LncRNA DANCR promotes the proliferation, migration, and invasion of tongue squamous cell carcinoma cells through miR-135a-5p/KLF8 axis. Cancer Cell Int. 19:302. 10.1186/s12935-019-1016-6 31827393 Zhou Y. Tian B. Tang J. Wu J. Wang H. Wu Z. (2020). SNHG7: a novel vital oncogenic lncRNA in human cancers. Biomed. Pharmacother. 124:109921. 10.1016/j.biopha.2020.109921 31986417 Zhu C. Y. Fan C. R. Zhang Y. L. Sun Q. X. Yan M. J. Wei W. (2020). LncRNA DANCR affected cell growth, EMT and angiogenesis by sponging miR-345-5p through modulating Twist1 in cholangiocarcinoma. Eur. Rev. Med. Pharmacol. Sci. 24 2321–2334. 10.26355/eurrev_202003_20498 Zhu Q. L. Li Z. Lv C. M. Wang W. (2019). MiR-187 influences cisplatin-resistance of gastric cancer cells through regulating the TGF-beta/Smad signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 23 9907–9914. 10.26355/eurrev_201911_19556